Genentech withdrew its psoriasis drug Raptiva from the market yesterday, citing the risk of developing progressive multifocal leukoencephalopathy (PML), a rare, often fatal brain infection. The drug ...
The US Food and Drug Administration has issued a public health advisory on Genentech's psoriasis drug Raptiva following four cases and three confirmed deaths from progressive multifocal ...
Subject: BLA 125075: Raptiva (efalizumab), Genentech Inc., for the proposed treatment of adult patients with moderate to severe plaque psoriasis. Background: The Dermatologic and Ophthalmic Drugs ...
Maidenhead, UK- The UK National Institute for Health and Clinical Excellence (NICE) has brought out guidance to effectively use biological therapies, Enbrel® (etanercept) and Raptiva ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback